e-learning
resources
Barcelona 2013
Monday, 09.09.2013
COPD mechanisms
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of roflumilast on lung function: Results from 180-days study in subjects With severe COPD
M. Ostrovskyy, I. Savelikhina, O. Varunkiv, M. Kulynych-Miskiv, G. Korzh (Ivano-Frankivsk, Ukraine)
Source:
Annual Congress 2013 –COPD mechanisms
Session:
COPD mechanisms
Session type:
Thematic Poster Session
Number:
2155
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Ostrovskyy, I. Savelikhina, O. Varunkiv, M. Kulynych-Miskiv, G. Korzh (Ivano-Frankivsk, Ukraine). Effect of roflumilast on lung function: Results from 180-days study in subjects With severe COPD. Eur Respir J 2013; 42: Suppl. 57, 2155
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Effect of tiotropium bromide on IFN-γ level: Results from 180-days study in moderate COPD patients with viral-induced exacerbations in anamnesis
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Effect of tiotropium bromide on collagen-IV level: Results from 180-days study in subjects with moderate COPD
Source: International Congress 2014 – Markers
Year: 2014
Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Heterogeneity inside group D COPD patients: About 827 cases
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Estimation of tiotropium efficacy at the COPD patients with group D
Source: International Congress 2015 – Different data in COPD
Year: 2015
Bacterial infection in hospitalized patients of acute exacerbation of COPD and their relation to lung function: A prospective study
Source: International Congress 2016 – Clinical and microbiological aspects of infections in COPD patients
Year: 2016
Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013
Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
The adherence to inhaled drugs in COPD patients: Effect on survival
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015
Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Development of a human COPD model-on-a-chip to mimic disease exacerbation (a small airway-on-a-chip model)
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Additive effect of targeted lung denervation plus drug in patients with COPD
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
Bronchodilator response of advanced lung function parameters depending on COPD severity
Source: International Congress 2016 – Functional assessment of the airways
Year: 2016
Value of adding treatment with lyophilized bacterial lysates in reducing COPD exacerbations in COPD patients risk group C and D
Source: International Congress 2014 – Non inflammatory monitoring of airway diseases
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept